

8th International Conference on Cachexia Sarcopenia and Muscle Wasting Join us in Paris, December 4-6, 2015



Journals

Log on

ussn

journal of the international society of sports nutrition

Search JISSN ▼ for Go

Author

Affiliations

Home

Articles

Authors

Reviewers

About this journal

My JISSN

Advanced search

Gateways

Research article

Can a standard dose of eicosapentaenoic acid (EPA) supplementation reduce the symptoms of delayed onset of muscle soreness?

David Houghton $^{\underline{1}\,\underline{2}}$ and Gladvs L Onambele $^{\underline{1}\,*}$

- * Corresponding author: Gladys L Onambele g.pearson@mmu.ac.uk
 - $^{
 m 1}$ Department of Exercise and Sports Science, Manchester Metropolitan University. Crewe Green Road, Crewe CW1 5DU, UK
 - 2 Institute for Cell and Molecular Bioscience, Framlington Place, Newcastle Upon Tyne, NE2 4HH,

For all author emails, please <u>log on</u>.

Journal of the International Society of Sports Nutrition 2012, 9:2

doi: 10.1186/1550-2783-9-2

Published: 31 January 2012

Abstract

Background

Unaccustomed exercise can result in delayed onset of muscle soreness (DOMS) which can affect athletic performance. Although DOMS is a useful tool to identify muscle damage and remodelling, prolonged symptoms of DOMS may be associated with the over-training syndrome. In order to reduce the symptoms of DOMS numerous management strategies have been attempted with no significant effect on DOMS-associated cytokines surge. The present study aimed to investigate the acute and chronic effects of a 2×180 mg per day dose of eicosapentaenoic acid (EPA) on interleukin-6 (IL-6) mediated inflammatory response and symptoms associated with DOMS.

Methods

Journal of the International Society of Sports Nutrition

Volume 9

Viewing options Abstract

Full text

PDF (519KB)

Associated

material

PubMed record Readers'

comments

Related literature

Cited by

Google blog

search

Other articles by

authors

on Google

Scholar

Houghton D

Onambele GL

■on PubMed

Houghton D Onambele GL

Related

articles/pages on Google

on Google

Seventeen healthy non-smoking females (age 20.4 \pm 2.1 years, height 161.2 \pm 8.3 cm and mass $61.48 \pm 7.4 \,\mathrm{kg}$) were randomly assigned to either placebo (N = 10) or EPA (N = 7). Serum IL-6, isometric and isokinetic (concentric and eccentric) strength, and rating of perceived exertion (RPE) were recorded on four occasions: i-prior to supplementation, ii-immediately after three weeks of supplementation (basal effects), iii-48 hours following a single bout of resistance exercise (acute training response effects), and iv-48 hours following the last of a series of three bouts of resistance exercise (chronic training response effects).

Results

There was only a group difference in the degree of change in circulating IL-6 levels. In fact, relative to the first baseline, by the third bout of eccentric workout, the EPA group had $103 \pm 60\%$ increment in IL-6 levels whereas the placebo group only had 80 ± 26% incremented IL-6 levels (P = 0.020). We also describe a stable multiple linear regression model which included measures of strength and not IL-6 as predictors of RPE scale.

Conclusion

The present study suggests that in doubling the standard recommended dose of EPA, whilst this may still not be beneficial at ameliorating the symptoms of DOMS, it counter intuitively appears to enhance the cytokine response to exercise. In a context where previous in vitro work has shown EPA to decrease the effects of inflammatory cytokines, it may in fact be that the doses required in vivo is much larger than current recommended amounts. An attempt to dampen the exerciseinduced cytokine flux in fact results in an over-compensatory response of this system.

Keywords: EPA; IL-6; resistance exercise and Delayed Onset Muscle Soreness

Sign up to receive new article alerts from Journal of the International Society of Sports Nutrition

Sign up

Scholar on PubMed

Tools Download references Download XML

Order reprints Post a

comment

Share this

Citeulike LinkedIn

Del.icio.us

Facebook

Email

Google+

Mendeley

Twitter

Reddit

with the latest news and content from JISSN and BioMed Central.

Sign up

Journal App





Terms and Conditions | Privacy statement | Press | Information for advertisers | Jobs at BMC | Support |

© 2015 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.

Springer

Try out the new beta version of our site

Take me there